Team Members2019-07-18T10:01:23-05:00
Anne-Marie Mes-Masson
Co-lead of the Canadian Tissue Repository Network (CTRNet), Associate Scientific Director, Basic and Translational Research at the CRCHUM

Dr. Anne-Marie Mes-Masson is a molecular oncologist who obtained her Ph.D. degree in the Department of Microbiology and Immunology of McGill University in 1984. From 1984 to 1986, she pursued her post-doctoral studies at UCLA's Molecular Biology Institute, researching the BCR-ABL gene implicated in chronic myelogenous leukemia. She was then appointed as a research associate at the Biotechnology Research Institute in Montreal. In 1989, Dr. Mes-Masson joined the Montreal Cancer Institute, and the University of Montreal's Department of Medicine, where she became a full professor in 2001.

From 2001-2017, Dr. Mes-Masson was the Scientific Director of the Montreal Cancer Institute and head of the Cancer axis at the Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM). Presently, Dr. Mes-Masson is the Associate Scientific Director, Basic and Translational Research at the CRCHUM. In 2003, Dr. Mes-Masson was nominated as director of the Cancer Research Network (Réseau de recherche sur le cancer RRCancer) for the Fonds de la recherche Québec - Santé (FRQS) where she has championed biobanking and accompanying standards for cancer biobanks in Quebec. Dr. Mes-Masson's research focuses on the development of cancer models and on the identification of molecular events implicated in ovarian and prostate cancer, and their translation into clinical tools for patient management. With her clinical collaborators, she has been instrumental in oncology biobanking at the CRCHUM.

Dr Mes-Masson has co-led several large translational research programs that include biobanking components. This includes the Terry Fox Research Institute COEUR program, a pan-Canadian program for the study of ovarian cancer. In addition, she has pioneered multiple novel ovarian cancer models to study cancer, including the development of novel cell lines, the description of 3D spheroid cultures for oncology, and more recently the combination of live ex vivo tissue with microfluidics for empirical drug testing.

Peter Watson
Co-lead of the Canadian Tissue Repository Network (CTRNet), Director of the University of British Columbia, Department of Pathology Office of Biobank Education and Research

Dr. Peter Watson is Director of the Biobanking and Biospecimen Research Services program at BC Cancer, an agency of the Provincial Health Services Authority (PHSA) in British Columbia. He also holds appointments as Senior Scientist and as Professor of Pathology, University of British Columbia, and as adjunct faculty at the University of Victoria.

He completed his medical training at the University of Cambridge and St Thomas's Hospital London, UK in 1983 and specialist training in Anatomic Pathology at the University of Manitoba in 1988. After fellowship training he established a career as a clinician scientist in 1993 at the University of Manitoba, and since 2005 has been at BC Cancer.

He currently combines a clinical practice as a breast pathologist with research interests in the molecular pathology of breast and ovarian cancer, and in biospecimen and biobanking resources. His research program focuses on biomarkers of breast tumour progression and response to therapies. This work has included the discovery, validation, elucidation of the mechanism of action, and exploration of the therapeutic potential of the S100A7 gene in breast cancer. This research has led to publication of over 175 scientific research papers.

He has also led provincial and national biobanking initiatives to advance translational cancer research. In addition, Dr. Watson serves as co-lead of the Canadian Tissue Repository Network (CTRNet) and he is currently the director of the University of British Columbia, Department of Pathology Office of Biobank Education and Research, serves on the executive of the Marble Arch International Working Group for Biobanking, and is Deputy Editor for the journal Biopreservation and Biobanking.

Rebecca Barnes
CTRNet Program Leader

Rebecca Barnes is the Program Leader for the Canadian Tumour Repository Network (CTRNet). She is responsible for helping the Executive and Management Committees with strategic planning and for overseeing some of CTRNet's current initiatives. Rebecca has a long-standing history with CTRNet, having been part of several task forces to help develop its tools and programs such as the Standard Operating Procedures and the Biobank Certification Program. She has worked in cancer research and biobanking for nearly 10 years, including positions managing biobanking programs in BC. In addition to her CTRNet role, in the past year Rebecca has taken on a new role to establish a "Permission to Contact for research" program for a regional health authority. The common thread for her various roles has been enhancement of health research capacity, through sustainable and standardized systems and processes. Rebecca holds a Bachelor of Science (Biology) and a Master's degree (Environmental Toxicology/Carcinogenesis).

Nicolas Luc
ATiM Project Leader
Nicolas Luc joined (CTRNet) in 2007. As the ATiM Project Leader he identifies, analyzes, prioritizes and controls new requirements and change requests for ATiM based on the business needs and the comments of network biobank experts.  He is also in charge of ongoing functional analysis and consolidating and communicating information to the developers.

In addition, Nicolas works actively with network biobanks as an ATiM software consultant. He analyses the gaps between the ATiM core version and specific biobank requirements, designs custom solutions, customizes the ATiM source code, deploys the customized versions and offers training and support to bank users.

Nicolas has also worked for 6 years on software development both for biomedical research and clinical research. Nicolas holds a Doctor of Pharmacy (Pharm.D.) and a Master’s degree in Bioinformatics.
Yaser Naderi
ATiM Developer
Yaser Naderi joined the team in 2017.  As an ATiM developer, his focus is on IT development and analysis. 
 
Yaser has written a book, titled “Assembly Programming,” and has 11 years of experience in teaching at a university level, including five of programming. He holds a Bachelor of Mathematics, Master of Science in Software Engineering, a Certificate in Applied Computing from the Université de Montréal, and a Certificate from the Collège de Bois-de-Boulogne in Big Data and Business Intelligence. In 2017, the Université de Montréal named Yaser as one of their Outstanding Students.
Ousmane Diallo
Informatics Analyst
Ousmane Diallo holds a degree in bioinformatics from the University of Montreal and a Master of Business Administration (MBA) from UQAM. He has extensive experience in programming, application development and database management for research groups (CRCHUM and MNI). Ousmane also has expertise in IT project management. He joined the ATiM team in August 2019.
Uladzimir Parkalau
IT Developer

Vlad joined the team from Belarus to work as a Computer & Systems Support Technician\IT Developer and is responsible for assisting the team with IT related biobank projects.

He has spent over four years working in the WEB development area and about three years in the healthcare sector. He was working on different projects to find and implement solutions for a variety of tasks. Besides his educations in Applied Computer Science with specialization in Network, System and Software Development.

Simon Dee
IT Project Manager

Simon Dee leads the application platform and services development for BC Cancer Agency's next-generation Bio-banking platform. He has experience in building technically challenging web-based applications and services. He has implemented the TTR (Tumour Tissue Repository) Information Systems Architecture and has also provided a cutting edge solution to support the BC Cancer Agency TTR Database Repository initiative of storing patient clinical data, pathologist annotations, outcomes, and specimen inventories for cancer research. This solution will be ground breaking in supporting and directing new research initiatives as well as allow the exploration of data mining not possible in the past.